B1 Vertaisarvioitu muu artikkeli (esim. pääkirjoitus, letter, comment) tieteellisessä lehdessä

International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity

Tekijät: Cohen, Ricardo V; Prager, Gerhard; le Roux, Carel W; Lingvay, Ildiko; Salminen, Paulina

Kustantaja: Elsevier BV

Julkaisuvuosi: 2025

Journal: Lancet Diabetes and Endocrinology

Tietokannassa oleva lehden nimi: The Lancet Diabetes & Endocrinology

Vuosikerta: 13

Numero: 9

Aloitussivu: 733

Lopetussivu: 736

ISSN: 2213-8587

DOI: https://doi.org/10.1016/S2213-8587(25)00198-6

Verkko-osoite: https://doi.org/10.1016/s2213-8587(25)00198-6

Julkaisussa olevat rahoitustiedot: 
RVC received grants from Johnson & Johnson and Medtronic (paid to institution); consulting fees from Regeneron; honoraria from Johnson & Johnson, Medtronic, Novo Nordisk, Merck, and Boston Scientific; participated on scientific advisory boards for Johnson & Johnson, Morphic Medical, and Medtronic; and is the President of the International Federation for the Surgery of Obesity (IFSO). GP received consulting fees from Medtronic, Johnson & Johnson, Novo Nordisk, and Eli Lilly; honoraria from Medtronic and Olympus; and is the immediate past President of the IFSO. CWlR received grants from the Irish Research Council, Health Research Board, Science Foundation Ireland, and Anabio; consulting fees for serving on advisory boards for Novo Nordisk, Eli Lilly, Boehringer Ingelheim, GI Dynamics, Herbalife, Altimmune, Irish Life Health, Amgen, Arrowhead, Roche, AstraZeneca, Keyron, Gila Pharmaceuticals, Metsera, Nymble, and AbbVie; honoraria from Novo Nordisk, Herbalife, and Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Rhythm Pharmaceuticals, and Currax Pharmaceuticals; support for attending meetings or travel from Novo Nordisk, Herbalife, Johnson & Johnson, Eli Lilly, and Boehringer Ingelheim; serves on the board for the Irish Society for Nutrition and Metabolism (unpaid); payment for serving on scientific advisory boards for Metsera and Nymble; and is the co-owner of the My Best Weight and Beyond BMI obesity clinics. IL received grants from Boehringer Ingelheim, Novo Nordisk, and Dexcom; consulting fees from AbbVie, Altimmune, Alveus Therapeutics, Amgen, Antag Therapeutics, AstraZeneca, Bayer, Betagenon AB, Bioio, Biomea, Boehringer Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen, Johnson & Johnson, Juvena, Keros Therapeutic, Inc, Mediflix, Merck, Metsera, Neurocrine, Novo Nordisk (personal and to institute), Pharmaventures, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Source Bio, Structure Therapeutics, Target RWE, Terns Pharma, The Comm Group, WebMD, and Zealand Pharma; honoraria from Novo Nordisk and AstraZeneca; support for attending meetings from Novo Nordisk, AstraZeneca, and Neurocrine; and participated on data safety monitoring boards for AbbVie, Altimmune, Alveus Therapeutics, Amgen, Antag Therapeutics, AstraZeneca, Bayer, Betagenon AB, Bioio, Biomea, Boehringer Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen, Johnson & Johnson, Juvena, Keros Therapeutic, Mediflix, Merck, Metsera, Neurocrine, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Source Bio, Structure Therapeutics, Target RWE, Terns Pharma, The Comm Group, WebMD, and Zealand Pharma. PS received grants from the Sigrid Jusélius Foundation, Academy of Finland, and European Research Council; honoraria from Novo Nordisk; participated on a data safety monitoring board for GM Solutions; is the President of the IFSO European Chapter; and is the President-elect of the IFSO.